fashion -WSS

fashion

author：hotspot 2025-09-06 02:16:24 - browse：75238

Adam's take main illustration — Molly Ferguson/STAT

Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome.

What sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials. Twice last year, first in February and then in December, Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.

If blarcamesine fails to achieve the pre-determined goals of clinical trials, the thinking apparently goes, then just make a post-hoc change to the study goals.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Americans' trust in science, scientist continues decline: Report

entertainment

WSS

Patients' immediate access to test results puts radiologists in a bind

Chemotherapy shortages won’t get better under Biden’s latest plan

FDA approves first blood sugar monitor without finger pricks

Charges dismissed against white woman who spat on Black woman during protests in Connecticut

PrEP can help anyone prevent HIV. Why do so few people take it?

Congenital heart disease patients face new threat of heart failure

hotspot

fashion

entertainment

Jerome Adams on the need for new antivirals for Covid

What causes an itch? Researchers may have solved the mystery

Dobbs anniversary: the lost opportunity of abortion as health care

4 missing after record

How one medical school became remarkably diverse

Statins reduce cardiovascular risk in people living with HIV

Alkermes shareholders re

Sophia Smith scores twice for US in in 3

Jerome Adams on the need for new antivirals for Covid

How to protect coverage of PrEP

hotspot

Men with early prostate cancer can safely opt out of treatment

After sickle

Pfizer plans to depart BIO

In diabetes hearing, Sanders takes on a new foe: food makers

CMS should re

FAMU bans football players from facility after release of rap video shot in team's locker room

Wikipedia

knowledge

focus

focus